0.059
120.15%
+0.0322
After Hours:
.059
Geovax Labs Inc stock is currently priced at $0.059, with a 24-hour trading volume of 13,554.
It has seen a +120.15% increased in the last 24 hours and a +20.16% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.028 pivot point. If it approaches the $0.0326 resistance level, significant changes may occur.
Previous Close:
$0.0268
Open:
$0.06
24h Volume:
13,554
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+68.57%
1M Performance:
+20.16%
6M Performance:
+0.00%
1Y Performance:
+0.00%
Geovax Labs Inc Stock (GOVXW) Company Profile
Name
Geovax Labs Inc
Sector
Industry
Phone
678 384 7220
Address
1900 Lake Park Drive, Suite 380, Smyrna
Geovax Labs Inc Stock (GOVXW) Latest News
GeoVax announces $1.3 million direct offering By Investing.com - Investing.com Australia
Investing.com Australia
GeoVax announces $1.3 million direct offering - Investing.com ZA - Investing.com South Africa
Investing.com South Africa
GeoVax announces $1.3 million direct offering - Investing.com India
Investing.com India
GeoVax announces $1.3 million direct offering By Investing.com - Investing.com
Investing.com
Earnings call: GeoVax reports progress on key vaccine trials - Investing.com Australia
Investing.com Australia
Earnings call: GeoVax reports progress on key vaccine trials - Investing.com Canada
Investing.com Canada
Geovax Labs Inc Stock (GOVXW) Financials Data
There is no financial data for Geovax Labs Inc (GOVXW). Check out other stocks for more information.
About Geovax Labs Inc
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Cap:
|
Volume (24h):